Biogen Inc. (BIIB)
Healthcare · Drug Manufacturers - General · Data as of 2026-10-22
Bottom line
BIIB is trading at a premium to its history, near its historical resistance zone, and recent volume suggests money flowing out. Historically, this combination has called for extra caution. Past patterns are not a guarantee of future results.
Valuation — Trading at a premium (Red)
BIIB trades at 45× earnings, above its own 5-year average of 17× and above similar healthcare companies we track (28×, 53 peers). Investors are currently paying more per dollar of earnings than usual. Its free-cash-flow yield is about 7.9%. Its current multiple sits around the 98th percentile of its own last five years — near the top of its own range.
Price zones — Near its historical resistance zone (Red)
At $253.84, the stock is close to the upper end of its recent range. Over the past year BIIB has traded between $138.00 and $254.41; its historical support zone sits near $222.58 and resistance near $254.41. It is above both its 50- and 200-day averages, which has historically signalled an uptrend.
52-week range $138.00–$254.41 · 50-day average $222.58 · 200-day average $199.13
Money flow — Money is flowing out (Red)
Recent trading in BIIB shows more volume on falling days than rising days, a pattern often described as distribution. Volume on up days has been about 1.1× volume on down days over the last 30 sessions.
Dividends & company facts
BIIB doesn't pay a dividend, but it bought back $10 million of its shares in fiscal 2025, about 0.03% of its market value. Its share count rose 1.9% over the past year.
- Buybacks
- 0.03% (fiscal 2025)
- Shares, past year
- +1.9%
- Revenue, 12 months
- $9.9B
- Profit, 12 months
- $835M
- Employees
- 7,500
- CEO
- Christopher A. Viehbacher
- Headquarters
- Cambridge, MA
- Listed since
- 1991 · NASDAQ
About the company
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA.
Related stocks
一句话结论
BIIB 相对自身历史处于溢价水平，接近其历史阻力区，近期成交量显示资金正在流出。从历史来看，这样的组合需要格外谨慎。过去的形态并不能保证未来的结果。
估值 — 相对自身历史处于溢价水平
BIIB 目前的市盈率为 45×，高于其自身 5 年平均的 17×，并且高于我们追踪的同类Healthcare公司（28×，53 家）。投资者目前为每一美元盈利付出的价格高于以往。其自由现金流收益率约为 7.9%。它当前的估值倍数大约位于自身过去五年分布的第 98 百分位——接近自身区间的顶部。
价格区间 — 接近其历史阻力区
目前价格为 $253.84，接近其近期区间的上沿。过去一年 BIIB 的价格在 $138.00 到 $254.41 之间波动；其历史支撑区在 $222.58 附近，阻力区在 $254.41 附近。它同时位于 50 日和 200 日均线上方，这在历史上通常对应上升趋势。
资金流向 — 资金正在流出
BIIB 近期下跌日的成交量高于上涨日，这种形态常被称为派发。过去 30 个交易日，上涨日的成交量约为下跌日的 1.1×。
股息与公司概况
BIIB 不派发股息，但在 2025 财年回购了 1,000万美元 的股票，约占市值的 0.03%。其股数过去一年增加了 1.9%。
UnderTheLight 用直白的语言解释股票——估值、价格区间与资金流向。它只描述数据，不构成任何投资建议。
UnderTheLight explains stocks in plain English — valuation, price zones and money flow as traffic lights, recomputed nightly. It describes data; it is not investment advice and never recommends a trade.